Susquehanna International Group, LLP Annexon, Inc. Put Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	SELL	$1.38 - $2.73 $4,830 - $9,555	-3,500 Reduced 11.33%	27,400 $65,000
Q1 2025 May 14, 2025	SELL	$1.93 - $5.5 $104,413 - $297,550	-54,100 Reduced 63.65%	30,900 $59,000
Q4 2024 Feb 14, 2025	SELL	$4.44 - $7.63 $125,208 - $215,166	-28,200 Reduced 24.91%	85,000 $436,000
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $511,860 - $820,800	-114,000 Reduced 50.18%	113,200 $670,000
Q2 2024 Aug 15, 2024	BUY	$4.33 - $6.79 $612,262 - $960,106	141,400 Added 164.8%	227,200 $1.11 Million
Q1 2024 May 07, 2024	BUY	$4.03 - $7.81 $227,695 - $441,265	56,500 Added 192.83%	85,800 $615,000
Q4 2023 Feb 14, 2024	BUY	$1.63 - $4.63 $21,516 - $61,116	13,200 Added 81.99%	29,300 $133,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $3.84 $253,896 - $457,728	-119,200 Reduced 88.1%	16,100 $37,000
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $284,130 - $861,861	135,300 New	135,300 $476,000
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $9,576 - $13,881	2,100 Added 1.03%	206,900 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $425,250 - $751,842	113,400 Added 124.07%	204,800 $1.27 Million

139

96.4M

63.4K

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $150M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.